论文部分内容阅读
一种可植入式的抗癫痫发作装置经美国食品药品管理局批准后,现正进行扩大的临床试验。在15个中心已有多至100例病人参加了第2期的临床试验。这种装置可植入于左锁骨处皮下,有一条金属丝与颈部的迷走神经相连接。该装置通过迷走神经把微弱的电讯号传播至脑的网状系统。这些讯号降低了大脑对诱发癫痫发作的刺激或条件的敏感性。这个装置
An implantable antiepileptic device is undergoing an expanded clinical trial with the approval of the U.S. Food and Drug Administration. Up to 100 patients have been enrolled in Phase 2 clinical trials in 15 centers. This device can be implanted in the skin at the left clavicle, a metal wire and vagus nerve connected to the neck. The device transmits weak electrical signals to the brain’s reticular system via the vagus nerve. These signals reduce the brain’s sensitivity to stimuli or conditions that induce seizures. This device